RADIOLABELED MET BINDING PROTEINS FOR IMMUNO-PET IMAGING

Organization Name

Inventor(s)

William Olson of Yorktown Heights NY (US)

RADIOLABELED MET BINDING PROTEINS FOR IMMUNO-PET IMAGING - A simplified explanation of the abstract

This abstract first appeared for US patent application 18400943 titled 'RADIOLABELED MET BINDING PROTEINS FOR IMMUNO-PET IMAGING

Simplified Explanation

This patent application discusses the use of radiolabeled anti-MET antibodies and MET×MET bispecific antibodies in immuno-PET imaging for detecting MET proteins in subjects with Met-expressing tumors.

Methods for detecting MET proteins in a subject or sample are provided.
Methods for monitoring the efficacy of treatment of Met-expressing tumors are included.

Key Features and Innovation

Use of radiolabeled anti-MET antibodies and MET×MET bispecific antibodies in immuno-PET imaging.
Detection of MET proteins in subjects with Met-expressing tumors.
Monitoring the efficacy of treatment for Met-expressing tumors.

Potential Applications

The technology can be used in the medical field for diagnosing and monitoring Met-expressing tumors.

Problems Solved

This technology addresses the need for accurate detection of MET proteins in Met-expressing tumors and monitoring the effectiveness of treatment.

Benefits

Improved accuracy in detecting MET proteins.
Enhanced monitoring of treatment efficacy for Met-expressing tumors.

Commercial Applications

The technology has potential commercial applications in the healthcare industry for cancer diagnosis and treatment monitoring.

Questions about Anti-MET Antibodies and MET×MET Bispecific Antibodies

1. How do radiolabeled anti-MET antibodies work in immuno-PET imaging? 2. What are the benefits of using MET×MET bispecific antibodies in detecting Met-expressing tumors?

Ensure the article is comprehensive, informative, and optimized for SEO with appropriate keyword usage and interlinking. Use varied sentence structures and natural language to avoid AI detection. Make the content engaging and evergreen by focusing on the lasting impact and relevance of the technology.

Original Abstract Submitted

Radiolabeled anti-MET antibodies and MET×MET bispecific antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of MET proteins in a subject or sample and methods of monitoring efficacy of treatment of a Met expressing tumor.